Kyntra Bio Inc (NASDAQ:KYNB) Given Average Rating of “Moderate Buy” by Analysts

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have earned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $30.00.

A number of research firms have recently weighed in on KYNB. Weiss Ratings reiterated a “sell (d)” rating on shares of Kyntra Bio in a report on Tuesday, June 16th. Oppenheimer started coverage on Kyntra Bio in a report on Monday. They set an “outperform” rating on the stock. Wall Street Zen raised Kyntra Bio from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Finally, Rodman & Renshaw assumed coverage on Kyntra Bio in a research report on Tuesday, June 9th. They issued a “buy” rating and a $30.00 price objective on the stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC purchased a new stake in shares of Kyntra Bio Inc (NASDAQ:KYNB) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned approximately 0.26% of Kyntra Bio at the end of the most recent reporting period. 72.71% of the stock is currently owned by institutional investors and hedge funds.

Kyntra Bio Stock Down 5.0%

Shares of NASDAQ:KYNB traded down $0.38 during trading on Monday, reaching $7.25. 19,563 shares of the company traded hands, compared to its average volume of 25,571. The stock has a market capitalization of $29.35 million, a price-to-earnings ratio of 0.18 and a beta of 0.96. Kyntra Bio has a 52-week low of $5.37 and a 52-week high of $12.60. The firm’s fifty day simple moving average is $7.00.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.